Section of Medical Oncology, Department of Surgical, Oncological, and Oral Sciences, University of Palermo, Palermo, Italy.
Academic Unit of Medical Oncology, Institute for Cancer Treatment and Research, Policlinico Hospital San Martino, Genoa, Italy.
Radiol Med. 2019 Apr;124(4):259-265. doi: 10.1007/s11547-018-0883-6. Epub 2018 Apr 4.
Soft tissue sarcomas (STSs) represent a rare and heterogeneous group of solid tumours derived from mesenchymal progenitors and account for 1% of all adult malignancies. Although in the last decade anthracycline-based chemotherapy single agent or in combinations has been able to improve clinical benefits, prognosis is still poor and STSs represent an important unmet medical need. Continuous advances in cancer genetics and genomics have contributed to change management paradigms of STSs as it occurred for other solid tumours. Several treatments have been recently developed with the specific aim of targeting different cell pathways and immune-checkpoints that have been recognized to drive tumour progression. The following attempts to provide a review of literature focusing on the available data concerning novel treatments and future prospective for the management of metastatic STSs.
软组织肉瘤（STS）是一种罕见且异质性的实体肿瘤，来源于间充质祖细胞，占所有成人恶性肿瘤的 1%。尽管在过去十年中，基于蒽环类药物的化疗单药或联合治疗已能够提高临床获益，但预后仍然较差，STS 仍然是一个重要的未满足的医疗需求。癌症遗传学和基因组学的不断进步，改变了 STS 的治疗模式，就像其他实体肿瘤一样。最近已经开发了几种治疗方法，其目的是靶向不同的细胞途径和免疫检查点，这些途径和检查点已被认为可推动肿瘤的进展。以下尝试提供对文献的综述，重点关注关于转移性 STS 治疗的新数据和未来前景。
